International Myeloma Foundation (IMF) Accelerates Global Expansion with Appointment of Prof. Jean-Luc Harousseau MD

Renowned researcher to help accelerate IMF programs in Asia and Europe

Jan 07, 2016, 12:26 ET from The International Myeloma Foundation

NORTH HOLLYWOOD, Calif., Jan. 7, 2016 /PRNewswire/ -- The International Myeloma Foundation (IMF) – improving the quality of life of myeloma patients while working toward prevention and a cure – is pleased to announce that renowned French myeloma researcher Prof. Jean-Luc Harousseau, MD is joining the organization to help accelerate the IMF's global expansion and outreach efforts in Asia and Europe.

"I am thrilled and honored that Prof. Harousseau is joining our global team," said IMF President Susie Novis Durie. "As Medical Education and Research Consultant, Dr. Harousseau's background and expertise will enhance our global programs. We've had the pleasure of working closely with Dr. Harousseau for many many years, and he's been a dear friend – not only to the IMF, but to myeloma patients around the world."

"Jean-Luc Harousseau brings extensive experience in myeloma treatment and research to his new position with the IMF," said IMF Chairman Dr. Brian Durie. "In addition, his experience on the global stage makes him perfectly suited to playing an important role in our growing patient education and outreach efforts around the world."

Recently retired from his position as professor of hematology at the University of Nantes, France—a position he held since 1980—Prof. Harousseau served as Chairman of the French National Authority for Health (HAS) from 2011 through 2015. He served as Director of the Cancer Center Rene Gauducheau in Nantes from 2008 to 2011. From 1984 to 2008, Prof. Harousseau was Head of the Department of Hematology at University Hospital.

Prof. Harousseau was a founding member and served as President of the Intergroupe Français du Myélome (IFM), whose clinical trials have contributed significantly to the major improvements in the prognosis of myeloma. Recipient of the 2005 Waldenström Award and the 2009 Robert A. Kyle Lifetime Achievement Award for his work in the field of multiple myeloma, he has contributed to more than 500 peer-reviewed publications, including the New England Journal of Medicine, Blood, and the Journal of Clinical Oncology.

In his new role with the IMF, Prof. Harousseau will help increase access to treatment for myeloma patients globally. His vast experience working with policymakers in France gives him the credentials and inside knowledge to make change happen. "France has an independent body in charge of improving quality of care and patient safety," he said. "One of its most important roles is to evaluate the benefit/risk ratio and the efficiency of new drugs in order to make decisions about their reimbursement and pricing."

Celebrating its 25th anniversary, the International Myeloma Foundation (IMF) is the oldest and largest foundation focusing specifically on multiple myeloma. The Foundation's reach extends to more than 400,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure by focusing on four key areas: research, education, support, and advocacy. The IMF has conducted more than 250 educational seminars worldwide, maintains a world-renowned InfoLine, and in 2001, established the International Myeloma Working Group (IMWG), a collaborative research initiative focused on improving myeloma treatment options for patients. In 2013, the IMF launched the Black Swan Research Initiative®, a groundbreaking research project aimed at curing myeloma. The IMF can be reached at (800) 452-CURE (2873). The global website is Follow the IMF on Twitter @IMFmyeloma.

Logo -


SOURCE The International Myeloma Foundation